These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18542774)

  • 1. Early versus late sacral neuromodulation and systematic reviews.
    Herschorn S
    Can Urol Assoc J; 2007 Jun; 1(2):111-2. PubMed ID: 18542774
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of OnabotulinumtoxinA versus sacral neuromodulation for refractory urinary urge incontinence: A systematic review and meta-analysis of randomized controlled trials.
    Niu HL; Ma YH; Zhang CJ
    Int J Surg; 2018 Dec; 60():141-148. PubMed ID: 30415088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacral neuromodulation for female pelvic floor disorders.
    El-Azab AS; Siegel SW
    Arab J Urol; 2019 Mar; 17(1):14-22. PubMed ID: 31258941
    [No Abstract]   [Full Text] [Related]  

  • 4. Sacral neuromodulation outcomes for the treatment of refractory idiopathic detrusor overactivity stratified by indication: Lack of anticholinergic efficacy versus intolerability.
    Davis T; Makovey I; Guralnick ML; O'Connor RC
    Can Urol Assoc J; 2013; 7(5-6):176-8. PubMed ID: 23069697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial.
    Harvie HS; Amundsen CL; Neuwahl SJ; Honeycutt AA; Lukacz ES; Sung VW; Rogers RG; Ellington D; Ferrando CA; Chermansky CJ; Mazloomdoost D; Thomas S
    J Urol; 2020 May; 203(5):969-977. PubMed ID: 31738113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: impact on fecal incontinence symptoms and sexual function.
    Andy UU; Amundsen CL; Honeycutt E; Markland AD; Dunivan G; Dyer KY; Korbly NB; Bradley M; Vasavada S; Mazloomdoost D; Thomas S;
    Am J Obstet Gynecol; 2019 Nov; 221(5):513.e1-513.e15. PubMed ID: 31211964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of sacral neuromodulation in treating chronic pain related to painful bladder syndrome/interstitial cystitis in adults.
    Srivastava D
    J Anaesthesiol Clin Pharmacol; 2012 Oct; 28(4):428-35. PubMed ID: 23225919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Trial of Sacral Neuromodulation for Refractory Overactive Bladder Syndrome in Korean Patients.
    Moon KH; Han JY; Kim JH; Lee HN; Lee KS; Lee JG; Oh SJ; Yoon HN; Choo MS
    Low Urin Tract Symptoms; 2014 Sep; 6(3):175-9. PubMed ID: 26663601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Chronic, Conscious Large Animal Platform to Quantify Therapeutic Effects of Sacral Neuromodulation on Bladder Function.
    Brink TS; Zimmerman PL; Mattson MA; Su X; Nelson DE
    J Urol; 2015 Jul; 194(1):252-8. PubMed ID: 25661299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term cost-effectiveness analysis of sacral neuromodulation in the treatment of severe faecal incontinence.
    de Miguel Valencia MJ; Cabasés Hita JM; Sánchez Iriso E; Oteiza Martínez F; Alberdi Ibañez I; Álvarez López A; Ortiz Hurtado H; de Miguel Velasco MJ
    Colorectal Dis; 2023 Sep; 25(9):1821-1831. PubMed ID: 37547929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacral neuromodulation for treatment of lower urinary tract dysfunction.
    Hohenfellner M; Dahms SE; Matzel K; Thüroff JW
    BJU Int; 2000 May; 85 Suppl 3():10-9; discussion 22-3. PubMed ID: 11954192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacral root neuromodulation in the treatment of various voiding and storage problems.
    Shaker H; Hassouna MM
    Int Urogynecol J Pelvic Floor Dysfunct; 1999; 10(5):336-43. PubMed ID: 10543344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effect of sacral neuromodulation on video-urodynamic parameters of neurogenic lower urinary tract dysfunction in a patient with vesicoureteral reflux: a case report.
    Meng L; Tian Z; Wang M; Liu X; Ma T; Wang J; Zhang W; Zhang Y
    Ann Palliat Med; 2022 Apr; 11(4):1568-1574. PubMed ID: 35523758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness of sacral neuromodulation in patients with Parkinson's disease].
    Millet C; Vedrine N; Descotes JL; Ruffion A; Durif F; Guy L
    Prog Urol; 2022 Sep; 32(10):664-671. PubMed ID: 35027284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single Institutional Experience with Single Stage Sacral Neuromodulation: Cost Savings and Outcomes in a Contemporary Case Series.
    Lee W; Artenstein D; Tenggardjaja CF; Lee UJ; Lucioni A; Reyblat P; Kobashi KC
    J Urol; 2020 Mar; 203(3):604-610. PubMed ID: 31584846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real World Performance of Sacral Neuromodulation and OnabotulinumtoxinA for Overactive Bladder: Focus on Safety and Cost.
    Chughtai B; Clemens JQ; Thomas D; Sun T; Ghomrawi H; Sedrakyan A
    J Urol; 2020 Jan; 203(1):179-184. PubMed ID: 31347949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation?
    Amin K; Moskowitz D; Kobashi KC; Lee UJ; Lucioni A
    J Urol; 2019 May; 201(5):973-978. PubMed ID: 30694936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific Changes in Brain Activity during Urgency in Women with Overactive Bladder after Successful Sacral Neuromodulation: A Functional Magnetic Resonance Imaging Study.
    Weissbart SJ; Bhavsar R; Rao H; Wein AJ; Detre JA; Arya LA; Smith AL
    J Urol; 2018 Aug; 200(2):382-388. PubMed ID: 29630979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal incontinence treated by sacral neuromodulation: Long-term follow-up of 325 patients.
    Janssen PT; Kuiper SZ; Stassen LP; Bouvy ND; Breukink SO; Melenhorst J
    Surgery; 2017 Apr; 161(4):1040-1048. PubMed ID: 28159117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.